Gilead Sciences, Inc. has voluntarily recalled 53,473 vials of Veklury (remdesivir) for injection, 100 mg/vial. The recall was initiated following a customer complaint and an investigation that confirmed the presence of glass particulates within the medication. This drug is an antiviral medication administered by healthcare providers in hospital settings via intravenous injection. To date, no incidents or injuries have been reported in connection with this recall.
If glass particulates are present in an injectable medication, they can be introduced into the bloodstream and travel to vital organs. This can lead to serious or life-threatening inflammation or injury in the heart, lungs, or brain. No reports of injuries have been received.
Quantity: 53,473 vials
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.